- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07946380
Mesopancreas Excision in Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma (MESO-PDAC)
Mesopancreas Excision Versus Standard Dissection During Pancreaticoduodenectomy for Resectable Pancreatic Ductal Adenocarcinoma: A Single-Center Randomized Controlled Trial
Pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, is treated when it arises in the head of the pancreas and can be removed by an operation called pancreaticoduodenectomy (the Whipple operation), followed by chemotherapy. Even after this operation the cancer returns in most patients. One important reason is that microscopic cancer cells are often left at the cut edges of the removed tissue, especially at the edge facing the superior mesenteric artery, the main artery that supplies the intestine. The tissue in this area, behind the head of the pancreas, is called the mesopancreas. It contains fat, lymph vessels, lymph nodes and nerves, through which pancreatic cancer commonly spreads.
Total mesopancreas excision is a refinement of the standard operation. The surgeon removes the whole mesopancreas in one piece together with the head of the pancreas by dissecting directly along the right side of the superior mesenteric artery, in the same way that the whole fatty envelope of the rectum is removed in rectal cancer surgery. Studies that compared patients operated on with and without this technique suggest that it may leave fewer cancer cells behind and reduce the chance of the cancer returning in the operated area, without increasing complications. Those studies were not randomized, however, so it is still unknown whether the technique itself is responsible for these benefits.
In this single-center randomized controlled trial, 110 adults with removable (resectable) cancer of the head of the pancreas will be assigned by chance, during the operation and after the surgeon has confirmed that the tumor can be removed, to pancreaticoduodenectomy with total mesopancreas excision or to standard pancreaticoduodenectomy. Patients, and the doctors who examine the removed tissue and the follow-up scans, will not be told which operation was performed. The main question is whether total mesopancreas excision increases the proportion of patients in whom no cancer cells are found within 1 mm of any cut edge (an R0 resection). The trial will also compare complications, diarrhea, recovery, the number of lymph nodes removed, the chance and pattern of cancer recurrence, survival and quality of life over 2 years of follow-up.
Descripción general del estudio
Estado
Descripción detallada
BACKGROUND AND RATIONALE
Pancreaticoduodenectomy followed by adjuvant chemotherapy is the standard treatment for resectable pancreatic ductal adenocarcinoma (PDAC) of the pancreatic head, but most patients develop recurrence, often within 2 years (Groot et al., 2018). Microscopic involvement of the resection margins is a major cause of locoregional failure. When pancreaticoduodenectomy specimens are examined with a standardized protocol of multicolor inking and axial slicing and the 1-mm rule is applied, most PDAC resections are classified as R1 (Verbeke et al., 2006; Esposito et al., 2008; Campbell et al., 2009), and the mesopancreatic margin facing the superior mesenteric artery (SMA) is the most frequently involved site (Gaedcke et al., 2010).
The mesopancreas, introduced as a surgical concept by Gockel et al. (2007), is the retropancreatic compartment of adipose, lymphatic and neural tissue that extends from the pancreatic head and uncinate process to the SMA and the aorta. Total mesopancreas excision (TMpE), analogous to total mesorectal excision for rectal cancer, removes this compartment en bloc by a periadventitial dissection along the right side of the SMA (Adham and Singhirunnusorn, 2012; Kawabata et al., 2012; Inoue et al., 2015). Comparative series have reported higher R0 rates (Kawabata et al., 2012; Xu et al., 2017; Shyr et al., 2025) and larger lymph node yields with fewer locoregional recurrences (Xu et al., 2017; Quero et al., 2020) after TMpE than after standard pancreaticoduodenectomy. A 2024 meta-analysis of nine non-randomized studies (738 patients) found a higher R0 rate (risk ratio 1.24), fewer local recurrences (risk ratio 0.39) and no increase in overall morbidity or mortality, with a non-significant increase in postoperative diarrhea (da Silva et al., 2024). The 2026 international MESODELPHI consensus agreed on a unified definition and boundaries of the mesopancreas, favored TMpE for curative-intent surgery, and called for further investigation of its effect on survival (Leite et al., 2026). No randomized trial comparing TMpE with standard pancreaticoduodenectomy has been published (Ramia et al., 2018; da Silva et al., 2024).
At the Liver and GIT Hospital, Minia University, a single-arm cohort of 86 patients who underwent pancreaticoduodenectomy with mesopancreas excision for PDAC between 2018 and 2024 had an R0 rate of 84.9% under the Royal College of Pathologists 1-mm rule; recurrence developed in 52 patients (60.5%), with a locoregional component in 31 of them (Saleh et al., 2026). Because that study, like most of the literature, had no control group, the oncological benefit of TMpE over standard pancreaticoduodenectomy remains unproven and requires a randomized comparison.
OBJECTIVES AND HYPOTHESIS
The primary objective is to determine whether pancreaticoduodenectomy with TMpE increases the R0 resection rate, defined as tumor clearance of 1 mm or more at all resection margins, compared with standard pancreaticoduodenectomy in patients with resectable PDAC of the pancreatic head. The hypothesis is that TMpE increases the R0 rate from 60% to 85%.
The secondary objectives are to compare SMA-margin involvement, lymph node yield, locoregional and distant recurrence, disease-free and overall survival, postoperative morbidity (including pancreatic fistula, hemorrhage, delayed gastric emptying, chyle leak and diarrhea), recovery, delivery of adjuvant chemotherapy and quality of life between the two operations.
STUDY DESIGN AND SETTING
This is a single-center, randomized, parallel-group (1:1) superiority trial with masked participants and masked outcome assessors, conducted at the Department of Surgery, Liver and GIT Hospital, Faculty of Medicine, Minia University, Minya, Egypt. The protocol follows the SPIRIT 2025 statement, and the trial will be reported according to CONSORT 2025 and its extension for non-pharmacologic treatments.
SCREENING AND STAGING
Consecutive adults referred with a mass in the pancreatic head or uncinate process are screened. Staging consists of pancreatic-protocol contrast-enhanced multidetector CT of the chest, abdomen and pelvis within 4 weeks before surgery, serum CA19-9, and endoscopic ultrasound with fine-needle aspiration or biopsy when the multidisciplinary tumor board requires a tissue diagnosis. Resectability is defined by NCCN criteria (Tempero et al., 2021). Preoperative biliary drainage is reserved for cholangitis, severe jaundice or an expected delay to surgery, according to unit policy.
RANDOMIZATION AND ALLOCATION CONCEALMENT
A statistician not involved in recruitment or treatment generates the allocation sequence by computer, using permuted blocks of variable size (4 and 6) stratified by venous contact on preoperative CT (no contact versus contact of 180 degrees or less with the superior mesenteric vein or portal vein). Allocations are kept in sequentially numbered, opaque, sealed envelopes outside the operating room. Written informed consent is obtained before surgery. Randomization takes place during the operation, after exploration has excluded peritoneal and liver metastases and confirmed local resectability, when the circulating nurse opens the next envelope of the relevant stratum. Patients found to be unresectable before randomization are not randomized and are recorded as screening failures.
MASKING
The operating surgeons cannot be masked. Participants are not told their allocation until follow-up is complete. Specimens are sent to pathology labeled with the trial number only, with a request form that does not state the allocation, and a second pathologist re-measures the margin distances on the slides. Postoperative complications are graded, and follow-up imaging is reviewed for recurrence, by investigators who did not take part in the operation and are masked to allocation. The statistician analyzes a dataset in which the arms are coded.
INTERVENTIONS
Both arms: All operations are open pancreaticoduodenectomies, pylorus-preserving or pylorus-resecting according to tumor extent, performed by senior hepatopancreatobiliary surgeons of the unit who have used TMpE since 2018 and perform more than 50 pancreaticoduodenectomies per year. Both arms receive the ISGPS standard lymphadenectomy (stations 5, 6, 8a, 12b1, 12b2, 12c, 13a, 13b, 14a, 14b, 17a and 17b; Tol et al., 2014). Portal or superior mesenteric vein resection is performed in either arm when needed for tumor clearance. Reconstruction, drain policy, antibiotic and thromboembolic prophylaxis, and the enhanced-recovery pathway are the same in both arms.
Experimental arm (TMpE): An artery-first approach exposes the SMA at its origin to confirm the absence of arterial involvement. The mesopancreas is excised en bloc with the pancreatic head and uncinate process within these boundaries: the superior mesenteric vein/portal vein axis and the right semicircumference of the SMA anteriorly and medially; the adventitia of the inferior vena cava, left renal vein and aorta posteriorly; the origins of the celiac trunk and SMA superiorly; and the lower border of the uncinate process and the first jejunal vessels inferiorly. The SMA is dissected in the periadventitial plane over its right hemicircumference (about 180 degrees) from the aortic origin to the origin of the first jejunal artery. The inferior pancreaticoduodenal artery, or its common trunk with the first jejunal artery, is ligated at its origin, and the right-sided SMA nerve plexus is removed with the specimen while the left-sided plexus is preserved. Extension of the periarterial clearance up to 270 degrees is allowed only when periarterial tumor extension is suspected during surgery and is recorded as a protocol variation.
Control arm (standard pancreaticoduodenectomy): A conventional vein-first approach is used (Kocher maneuver, tunneling behind the pancreatic neck and transection of the neck). The uncinate process is divided from the superior mesenteric vein and from the right side of the SMA, ligating the pancreaticoduodenal branches close to the pancreas. The SMA is not dissected in the periadventitial plane, its nerve plexus is preserved, and the retropancreatic tissue is not excised as an en bloc compartment; station 14a and 14b nodes are removed superficial to the nerve plexus.
Surgical quality assurance: Standardized photographs of the operative field after resection and of the specimen are taken in every case and reviewed by an independent senior surgeon to confirm that the allocated technique was performed. Crossovers and protocol deviations are documented.
PATHOLOGY PROTOCOL
The surgeon marks the SMA margin and the superior mesenteric vein groove with sutures. Specimens are examined with a standardized protocol based on multicolor inking of the margins and surfaces, axial slicing perpendicular to the duodenal axis at 3 to 5 mm intervals, and extensive sampling (Verbeke et al., 2006). The minimum distance between tumor and each margin is measured microscopically. R0 is defined as clearance of 1 mm or more at all resection margins (SMA, superior mesenteric vein/portal vein groove, posterior, pancreatic neck, bile duct, and proximal and distal enteric margins). R1 is defined as tumor less than 1 mm from any resection margin and is subdivided into direct (0 mm) and indirect (more than 0 mm and less than 1 mm) involvement. Involvement of the anterior pancreatic surface is recorded separately. Lymph nodes are reported by station, staging follows the 8th edition of the AJCC/UICC TNM classification, and perineural, lymphovascular and retropancreatic soft-tissue invasion are recorded.
POSTOPERATIVE CARE, ADJUVANT THERAPY AND FOLLOW-UP
Complications are recorded prospectively for 90 days and graded by the Clavien-Dindo classification (Dindo et al., 2004) and the Comprehensive Complication Index (Slankamenac et al., 2013). Postoperative pancreatic fistula, delayed gastric emptying, post-pancreatectomy hemorrhage and chyle leak follow the ISGPS definitions (Bassi et al., 2017; Wente et al., 2007a; Wente et al., 2007b; Besselink et al., 2017). Diarrhea is graded by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 at every visit for 6 months. Adjuvant chemotherapy is decided by the clinical oncology team, which is masked to allocation: modified FOLFIRINOX for fit patients or gemcitabine plus capecitabine, planned for 6 months and started within 12 weeks of surgery (Neoptolemos et al., 2017; Conroy et al., 2018). Follow-up visits occur at 1, 3, 6, 9, 12, 18 and 24 months, with clinical examination and serum CA19-9 at each visit. Contrast-enhanced CT of the chest, abdomen and pelvis is performed at 3, 6, 9, 12, 18 and 24 months and whenever recurrence is suspected, with MRI, PET-CT or biopsy when needed. Recurrence is classified as locoregional (pancreatic or mesopancreatic bed around the SMA, celiac axis and superior mesenteric vein/portal vein, anastomoses, or regional lymph nodes), distant (liver, lungs, peritoneum, bone, non-regional lymph nodes or other organs) or combined, and is adjudicated by a radiologist masked to allocation. Quality of life is assessed with the EORTC QLQ-C30 at baseline and at 3, 6 and 12 months.
SAMPLE SIZE
The sample size is based on the primary outcome. The expected R0 rate is 60% after standard pancreaticoduodenectomy (Kawabata et al., 2012) and 85% after TMpE, based on the institutional series in which a comparable protocol (axial slicing, margin inking and the 1-mm rule) gave an R0 rate of 84.9% (Saleh et al., 2026). A difference of this size is consistent with the higher R0 rates reported in comparative series and with the mesopancreatic margin being the most common site of R1 resection (Gaedcke et al., 2010; da Silva et al., 2024). Detecting it with 80% power and a two-sided alpha of 0.05 (chi-square test) requires 49 participants per arm. Allowing 10% for post-randomization exclusions (final histology other than PDAC, or withdrawal), 55 participants per arm will be randomized (110 in total). Recruitment is planned over 12 months, from December 2026 to November 2027.
STATISTICAL ANALYSIS
The primary analysis follows a modified intention-to-treat approach: all randomized participants with histologically confirmed PDAC, analyzed in the arm to which they were allocated. A per-protocol analysis excluding crossovers and major protocol deviations is a sensitivity analysis. R0 rates are compared with the chi-square test and reported as the absolute risk difference and risk ratio with 95% confidence intervals; logistic regression adjusted for the stratification factor is a supportive analysis. Other categorical outcomes are compared with the chi-square or Fisher exact test, and continuous outcomes with the t-test or Mann-Whitney U test. Disease-free and overall survival are estimated by the Kaplan-Meier method, compared with the log-rank test and modeled with Cox regression adjusted for the stratification factor. Locoregional and distant recurrence are analyzed as cumulative incidence with death as a competing event (Gray test and Fine-Gray model). Quality-of-life scores are analyzed with linear mixed models. Prespecified subgroup analyses of the primary outcome are by venous contact and by tumor size on CT (2 cm or less versus more than 2 cm). Missing secondary outcome data are handled by multiple imputation if more than 5% are missing. All tests are two-sided at a significance level of 0.05; secondary outcomes are not adjusted for multiplicity and are interpreted as exploratory. Analyses are performed with SPSS version 26 and R.
DATA MANAGEMENT AND MONITORING
Data are recorded on standardized case report forms and entered into a password-protected database with coded identifiers; the primary outcome is verified against source documents for every participant. An independent data and safety monitoring board (a hepatopancreatobiliary surgeon, a clinical oncologist and a biostatistician, none involved in the trial) reviews unmasked safety data, including 90-day mortality, complications of Clavien-Dindo grade IIIa or higher, grade B or C pancreatic fistula and hemorrhage, and diarrhea of CTCAE grade 3 or higher, after 30 and after 55 participants have completed 90 days of follow-up, and may recommend modification or early termination for safety. No interim efficacy analysis is planned. Serious adverse events are reported to the Institutional Review Board according to its requirements.
ETHICS AND DISSEMINATION
The protocol was approved by the Institutional Review Board, Faculty of Medicine, Minia University (MUFMIRB approval number 1702:09/2025, 15 September 2025). The trial is conducted in accordance with the Declaration of Helsinki, ICH Good Clinical Practice and Egyptian Law No. 214 of 2020 on clinical medical research. All participants give written informed consent before surgery, including consent to randomization during the operation, and may withdraw at any time without any effect on their care. Results will be published in a peer-reviewed journal and reported on ClinicalTrials.gov regardless of the findings.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Saleh Khairy Saleh, MD
- Número de teléfono: +20 120 176 5401
- Correo electrónico: salehkhairy@mu.edu.eg
Ubicaciones de estudio
-
-
Minya Governorate
-
Minya, Minya Governorate, Egipto
- Liver and GIT Hospital, Faculty of Medicine, Minia University
-
Contacto:
- Saleh Khairy Saleh, MD
- Número de teléfono: +20 120 176 5401
- Correo electrónico: salehkhairy@mu.edu.eg
-
Investigador principal:
- Saleh Khairy Saleh, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age 18 to 75 years.
- Solid tumor of the pancreatic head or uncinate process with a cytological or histological diagnosis of pancreatic ductal adenocarcinoma or, when a tissue diagnosis is not available, imaging features typical of pancreatic ductal adenocarcinoma accepted by the multidisciplinary tumor board.
- Resectable disease according to NCCN criteria on pancreatic-protocol contrast-enhanced CT performed within 4 weeks before surgery: no arterial tumor contact (celiac axis, superior mesenteric artery or common hepatic artery), and no contact with the superior mesenteric vein or portal vein or contact of 180 degrees or less without vein contour irregularity.
- Planned upfront open pancreaticoduodenectomy with curative intent.
- ECOG performance status 0 or 1.
- American Society of Anesthesiologists (ASA) physical status I to III.
- Written informed consent, including consent to randomization during surgery.
- Confirmation at laparotomy, before randomization, of no peritoneal or liver metastases and no tumor involvement of the superior mesenteric artery, celiac axis or common hepatic artery.
Exclusion Criteria:
- Borderline resectable or locally advanced disease, or distant metastases, on preoperative staging.
- Previous chemotherapy, chemoradiotherapy or radiotherapy for the current tumor.
- Preoperative diagnosis of another tumor type, including ampullary, distal bile duct or duodenal carcinoma, neuroendocrine neoplasm, acinar cell carcinoma, solid pseudopapillary neoplasm or lymphoma.
- Planned total pancreatectomy or arterial resection.
- Planned laparoscopic or robotic pancreaticoduodenectomy.
- Previous pancreatic resection, or previous major surgery around the superior mesenteric vessels or in the retroperitoneum near the pancreas.
- Liver cirrhosis of Child-Pugh class B or C, or portal hypertension.
- Other active malignancy, or previous malignancy within 5 years other than non-melanoma skin cancer or carcinoma in situ of the cervix.
- Emergency surgery for bleeding or perforation.
- Pregnancy or breastfeeding.
- Inability to attend follow-up or to give informed consent.
- Participation in another interventional trial that could affect the study outcomes.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Pancreaticoduodenectomy With Total Mesopancreas Excision
Open pancreaticoduodenectomy using an artery-first approach with en bloc total mesopancreas excision: periadventitial dissection of the right hemicircumference (about 180 degrees) of the superior mesenteric artery from its aortic origin to the first jejunal artery, ligation of the inferior pancreaticoduodenal artery at its origin, and removal of the retropancreatic fat, lymphatic and neural tissue (including the right-sided superior mesenteric artery nerve plexus) down to the inferior vena cava, left renal vein and aorta, plus ISGPS standard lymphadenectomy. Reconstruction and perioperative care are identical to the control arm. |
Open pancreaticoduodenectomy (pylorus-preserving or pylorus-resecting) with an artery-first approach. The mesopancreas is excised en bloc with the pancreatic head and uncinate process within these boundaries: the superior mesenteric vein/portal vein axis and the right semicircumference of the superior mesenteric artery anteriorly and medially; the adventitia of the inferior vena cava, left renal vein and aorta posteriorly; the origins of the celiac trunk and superior mesenteric artery superiorly; and the lower border of the uncinate process inferiorly. The artery is cleared in the periadventitial plane over about 180 degrees on its right side from the aorta to the first jejunal artery, with ligation of the inferior pancreaticoduodenal artery at its origin; the left-sided nerve plexus is preserved. Extension up to 270 degrees is allowed only for suspected periarterial tumor extension. ISGPS standard lymphadenectomy.
Otros nombres:
|
|
Comparador activo: Standard Pancreaticoduodenectomy
Open pancreaticoduodenectomy using the conventional vein-first approach, with division of the uncinate process from the superior mesenteric vein and the right side of the superior mesenteric artery close to the pancreas, without periadventitial dissection of the artery or resection of its nerve plexus, plus ISGPS standard lymphadenectomy. Reconstruction and perioperative care are identical to the experimental arm. |
Open pancreaticoduodenectomy (pylorus-preserving or pylorus-resecting) using the conventional vein-first approach: Kocher maneuver, tunneling behind the pancreatic neck and neck transection, then division of the uncinate process from the superior mesenteric vein and from the right side of the superior mesenteric artery, with ligation of the pancreaticoduodenal branches close to the pancreas. The artery is not dissected in the periadventitial plane, its nerve plexus is preserved, and the retropancreatic tissue is not excised as an en bloc compartment. ISGPS standard lymphadenectomy (stations 5, 6, 8a, 12b1, 12b2, 12c, 13a, 13b, 14a, 14b, 17a and 17b), with station 14a and 14b nodes removed superficial to the nerve plexus.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
R0 Resection Rate (Tumor Clearance of 1 mm or More at All Resection Margins)
Periodo de tiempo: Final histopathology report, within 3 weeks after surgery
|
Proportion of participants with an R0 resection on final histopathology. R0 is defined as a minimum microscopic distance of 1 mm or more between tumor and every resection margin (superior mesenteric artery margin, superior mesenteric vein/portal vein groove margin, posterior margin, pancreatic neck transection margin, bile duct margin, and proximal and distal enteric margins), assessed with a standardized protocol of multicolor inking and axial slicing. Pathologists are masked to allocation, and a second pathologist re-measures margin distances on the slides. Analyzed in randomized participants with histologically confirmed pancreatic ductal adenocarcinoma. |
Final histopathology report, within 3 weeks after surgery
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Superior Mesenteric Artery (Mesopancreatic) Margin Involvement
Periodo de tiempo: Final histopathology report, within 3 weeks after surgery
|
Proportion of participants with tumor less than 1 mm from the inked superior mesenteric artery (mesopancreatic) margin on final histopathology. |
Final histopathology report, within 3 weeks after surgery
|
|
R1 Direct Resection Rate (Tumor at a Resection Margin)
Periodo de tiempo: Final histopathology report, within 3 weeks after surgery
|
Proportion of participants with tumor cells at the inked surface (0 mm) of any resection margin on final histopathology. |
Final histopathology report, within 3 weeks after surgery
|
|
Number of Lymph Nodes Examined
Periodo de tiempo: Final histopathology report, within 3 weeks after surgery
|
Total number of lymph nodes retrieved from the resection specimen and examined histologically. |
Final histopathology report, within 3 weeks after surgery
|
|
Locoregional Recurrence
Periodo de tiempo: From surgery up to 24 months
|
Cumulative incidence of locoregional recurrence (pancreatic or mesopancreatic bed around the superior mesenteric artery, celiac axis and superior mesenteric vein/portal vein, surgical anastomoses, or regional lymph nodes), isolated or combined with distant recurrence, diagnosed on contrast-enhanced CT with MRI, PET-CT or biopsy when required and adjudicated by a radiologist masked to allocation. Death without recurrence is treated as a competing event. |
From surgery up to 24 months
|
|
Distant Recurrence
Periodo de tiempo: From surgery up to 24 months
|
Cumulative incidence of recurrence in the liver, lungs, peritoneum, bone, non-regional lymph nodes or other distant sites, diagnosed and adjudicated as for locoregional recurrence. Death without recurrence is treated as a competing event. |
From surgery up to 24 months
|
|
Disease-Free Survival
Periodo de tiempo: From surgery up to 24 months
|
Time from surgery to first recurrence at any site or death from any cause, estimated by the Kaplan-Meier method and reported as the 2-year disease-free survival rate. |
From surgery up to 24 months
|
|
Overall Survival
Periodo de tiempo: From surgery up to 24 months
|
Time from surgery to death from any cause, estimated by the Kaplan-Meier method and reported as the 2-year overall survival rate. |
From surgery up to 24 months
|
|
Operative Time
Periodo de tiempo: During surgery
|
Time from skin incision to completion of skin closure, in minutes. |
During surgery
|
|
Intraoperative Blood Loss
Periodo de tiempo: During surgery
|
Estimated blood loss in milliliters, measured from suction volume and weighed swabs. |
During surgery
|
|
Overall Postoperative Morbidity
Periodo de tiempo: Within 90 days after surgery
|
Proportion of participants with at least one postoperative complication of any grade according to the Clavien-Dindo classification. |
Within 90 days after surgery
|
|
Major Postoperative Morbidity (Clavien-Dindo Grade IIIa or Higher)
Periodo de tiempo: Within 90 days after surgery
|
Proportion of participants with at least one complication of Clavien-Dindo grade IIIa or higher. |
Within 90 days after surgery
|
|
Comprehensive Complication Index
Periodo de tiempo: Within 90 days after surgery
|
Cumulative burden of all postoperative complications on a continuous scale from 0 (no complication) to 100 (death). |
Within 90 days after surgery
|
|
Clinically Relevant Postoperative Pancreatic Fistula (ISGPS Grade B or C)
Periodo de tiempo: Within 90 days after surgery
|
Proportion of participants with grade B or C postoperative pancreatic fistula according to the 2016 International Study Group of Pancreatic Surgery (ISGPS) definition. |
Within 90 days after surgery
|
|
Post-Pancreatectomy Hemorrhage (ISGPS Grade B or C)
Periodo de tiempo: Within 90 days after surgery
|
Proportion of participants with grade B or C post-pancreatectomy hemorrhage according to the ISGPS definition. |
Within 90 days after surgery
|
|
Delayed Gastric Emptying (ISGPS Grade B or C)
Periodo de tiempo: Within 90 days after surgery
|
Proportion of participants with grade B or C delayed gastric emptying according to the ISGPS definition. |
Within 90 days after surgery
|
|
Chyle Leak (ISGPS Grade B or C)
Periodo de tiempo: Within 90 days after surgery
|
Proportion of participants with grade B or C chyle leak according to the ISGPS definition. |
Within 90 days after surgery
|
|
Clinically Significant Postoperative Diarrhea (CTCAE Grade 2 or Higher)
Periodo de tiempo: Within 6 months after surgery
|
Proportion of participants with diarrhea of grade 2 or higher according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, assessed at every visit. |
Within 6 months after surgery
|
|
Unplanned Reoperation
Periodo de tiempo: Within 90 days after surgery
|
Proportion of participants who require an unplanned return to the operating room. |
Within 90 days after surgery
|
|
Length of Postoperative Hospital Stay
Periodo de tiempo: From surgery to discharge, up to 90 days
|
Number of days from surgery to hospital discharge. |
From surgery to discharge, up to 90 days
|
|
Hospital Readmission
Periodo de tiempo: Within 90 days after surgery
|
Proportion of participants readmitted to hospital after discharge. |
Within 90 days after surgery
|
|
90-Day Mortality
Periodo de tiempo: Within 90 days after surgery
|
Proportion of participants who die from any cause within 90 days after surgery. |
Within 90 days after surgery
|
|
Initiation of Adjuvant Chemotherapy Within 12 Weeks
Periodo de tiempo: Within 12 weeks after surgery
|
Proportion of participants who start adjuvant chemotherapy within 12 weeks after surgery. |
Within 12 weeks after surgery
|
|
Health-Related Quality of Life (EORTC QLQ-C30 Global Health Status)
Periodo de tiempo: Baseline and 3, 6 and 12 months after surgery
|
Global health status/quality of life score of the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire, from 0 to 100; higher scores indicate better quality of life. |
Baseline and 3, 6 and 12 months after surgery
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Minimum Tumor Clearance at the Superior Mesenteric Artery Margin
Periodo de tiempo: Final histopathology report, within 3 weeks after surgery
|
Microscopic distance, in millimeters, between the tumor and the inked superior mesenteric artery margin. |
Final histopathology report, within 3 weeks after surgery
|
|
Lymph Node Ratio
Periodo de tiempo: Final histopathology report, within 3 weeks after surgery
|
Number of metastatic lymph nodes divided by the number of lymph nodes examined. |
Final histopathology report, within 3 weeks after surgery
|
|
Metastasis in Lymph Nodes Along the Superior Mesenteric Artery (Station 14)
Periodo de tiempo: Final histopathology report, within 3 weeks after surgery
|
Proportion of participants with at least one metastatic station 14 lymph node. |
Final histopathology report, within 3 weeks after surgery
|
|
Tumor Invasion of the Retropancreatic Soft Tissue or Nerve Plexus
Periodo de tiempo: Final histopathology report, within 3 weeks after surgery
|
Proportion of participants with histological tumor invasion (direct, perineural or lymphovascular) of the resected retropancreatic soft tissue or nerve plexus. |
Final histopathology report, within 3 weeks after surgery
|
|
Anterior Pancreatic Surface Involvement
Periodo de tiempo: Final histopathology report, within 3 weeks after surgery
|
Proportion of participants with tumor at the inked anterior surface of the pancreas (0 mm). |
Final histopathology report, within 3 weeks after surgery
|
|
Pattern of First Recurrence
Periodo de tiempo: From surgery up to 24 months
|
Distribution of first recurrence as isolated locoregional, isolated distant, or combined locoregional and distant recurrence. |
From surgery up to 24 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Saleh Khairy Saleh, MD, Minia University
Publicaciones y enlaces útiles
Publicaciones Generales
- Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. doi: 10.1097/01.sla.0000133083.54934.ae.
- Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Buchler MW; European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017 Mar 11;389(10073):1011-1024. doi: 10.1016/S0140-6736(16)32409-6. Epub 2017 Jan 25.
- Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Chone L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.
- Slankamenac K, Graf R, Barkun J, Puhan MA, Clavien PA. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Ann Surg. 2013 Jul;258(1):1-7. doi: 10.1097/SLA.0b013e318296c732.
- Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, Neoptolemos JP, Padbury RT, Sarr MG, Traverso LW, Yeo CJ, Buchler MW. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007 Nov;142(5):761-8. doi: 10.1016/j.surg.2007.05.005.
- Wente MN, Veit JA, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, Neoptolemos JP, Padbury RT, Sarr MG, Yeo CJ, Buchler MW. Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery. 2007 Jul;142(1):20-5. doi: 10.1016/j.surg.2007.02.001.
- Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Moravek C, Nakakura EK, Narang AK, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Vollmer C, Wolff RA, Wolpin BM, Lynn B, George GV. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Apr 1;19(4):439-457. doi: 10.6004/jnccn.2021.0017.
- Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, Schirmacher P, Buchler MW. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008 Jun;15(6):1651-60. doi: 10.1245/s10434-008-9839-8. Epub 2008 Mar 20.
- Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, Allen P, Andersson R, Asbun HJ, Besselink MG, Conlon K, Del Chiaro M, Falconi M, Fernandez-Cruz L, Fernandez-Del Castillo C, Fingerhut A, Friess H, Gouma DJ, Hackert T, Izbicki J, Lillemoe KD, Neoptolemos JP, Olah A, Schulick R, Shrikhande SV, Takada T, Takaori K, Traverso W, Vollmer CM, Wolfgang CL, Yeo CJ, Salvia R, Buchler M; International Study Group on Pancreatic Surgery (ISGPS). The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017 Mar;161(3):584-591. doi: 10.1016/j.surg.2016.11.014. Epub 2016 Dec 28.
- Xu J, Tian X, Chen Y, Ma Y, Liu C, Tian L, Wang J, Dong J, Cui D, Wang Y, Zhang W, Yang Y. Total mesopancreas excision for the treatment of pancreatic head cancer. J Cancer. 2017 Sep 30;8(17):3575-3584. doi: 10.7150/jca.21341. eCollection 2017.
- Campbell F, Smith RA, Whelan P, Sutton R, Raraty M, Neoptolemos JP, Ghaneh P. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology. 2009 Sep;55(3):277-83. doi: 10.1111/j.1365-2559.2009.03376.x.
- Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006 Oct;93(10):1232-7. doi: 10.1002/bjs.5397.
- Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, Weiss MJ, Zheng L, Wolfgang CL, He J. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Ann Surg. 2018 May;267(5):936-945. doi: 10.1097/SLA.0000000000002234.
- Gaedcke J, Gunawan B, Grade M, Szoke R, Liersch T, Becker H, Ghadimi BM. The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. Langenbecks Arch Surg. 2010 Apr;395(4):451-8. doi: 10.1007/s00423-009-0494-8. Epub 2009 May 6.
- Gockel I, Domeyer M, Wolloscheck T, Konerding MA, Junginger T. Resection of the mesopancreas (RMP): a new surgical classification of a known anatomical space. World J Surg Oncol. 2007 Apr 25;5:44. doi: 10.1186/1477-7819-5-44.
- Adham M, Singhirunnusorn J. Surgical technique and results of total mesopancreas excision (TMpE) in pancreatic tumors. Eur J Surg Oncol. 2012 Apr;38(4):340-5. doi: 10.1016/j.ejso.2011.12.015. Epub 2012 Jan 20.
- Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. Eur J Surg Oncol. 2012 Jul;38(7):574-9. doi: 10.1016/j.ejso.2012.04.007. Epub 2012 May 9.
- Inoue Y, Saiura A, Yoshioka R, Ono Y, Takahashi M, Arita J, Takahashi Y, Koga R. Pancreatoduodenectomy With Systematic Mesopancreas Dissection Using a Supracolic Anterior Artery-first Approach. Ann Surg. 2015 Dec;262(6):1092-101. doi: 10.1097/SLA.0000000000001065.
- Quero G, Fiorillo C, Menghi R, Cina C, Galiandro F, Longo F, Sofo F, Rosa F, Tortorelli AP, Giustiniani MC, Inzani F, Alfieri S. Total mesopancreas excision for periampullary malignancy: a single-center propensity score-matched comparison of long-term outcomes. Langenbecks Arch Surg. 2020 May;405(3):303-312. doi: 10.1007/s00423-020-01873-4. Epub 2020 Apr 24.
- Shyr BS, Wang SE, Chen SC, Shyr YM, Shyr BU. Mesopancreas dissection level 3 for pancreatic head cancer in combined robotic/open pancreatoduodenectomy: a propensity score-matched study. Surg Endosc. 2025 Feb;39(2):1191-1199. doi: 10.1007/s00464-024-11475-6. Epub 2024 Dec 29.
- da Silva LFL, Belotto M, de Almeida LFC, Samuel J, Pereira LH, Albagli RO, de Araujo MS, Ramia JM. Radicality and safety of total mesopancreatic excision in pancreatoduodenectomy: a systematic review and meta-analysis. World J Surg Oncol. 2024 Aug 23;22(1):217. doi: 10.1186/s12957-024-03495-2.
- Leite LF, Belotto M, Sa de Araujo M, Menezes S, de Almeida LF, Hilal MA, Alcazar Lopez CF, Azagra JS, Balakrishnan A, Berrevoet F, Besselink MG, Blanco-Fernandez G, Boggi U, Chapa-Azuela O, Coimbra FJF, Dasari BVM, Dokmak S, Duarte AA, Falconi M, Oliveira AF, Fusai GK, Frigerio I, Gimenez M, Ielpo B, Inoue Y, Jarufe N, Chavarria EJ, Lesurtel M, Malleo G, Marchegiani G, Mazza O, de Oliveira CVC, O'Rourke N, Pandanaboyana S, Rangelova E, Sabater L, Satoi S, Sauvanet A, Serradilla-Martin M, Siriwardena AK, Sparrelid E, Starlinger P, Stattner S, Strobel O, Sturesson C, Villodre C, Werner J, Galvao do Amaral PC, Peixoto RD, Clavien PA, Ramia JM. International consensus on mesopancreas and total mesopancreas excision (MESODELPHI). HPB (Oxford). 2026 Oct;28(10):1311-1317. doi: 10.1016/j.hpb.2026.06.012. Epub 2026 Jun 30.
- Ramia JM, De-la-Plaza R, Manuel-Vazquez A, Lopez-Marcano A, Morales R. Systematic review of the mesopancreas: concept and clinical implications. Clin Transl Oncol. 2018 Nov;20(11):1385-1391. doi: 10.1007/s12094-018-1869-5. Epub 2018 Apr 19.
- Saleh SK, Saleh AG, Mohamed TA, Hendy MM, Farahat MS, Boushra ST, Kamil CM, Saleh RK. Mesopancreas excision in pancreatic ductal adenocarcinoma: recurrence patterns - a single-arm descriptive study. World J Surg Oncol. 2026 Jun 22;24(1):265. doi: 10.1186/s12957-026-04459-4.
- Tol JA, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M, Andren-Sandberg A, Asbun HJ, Bockhorn M, Buchler MW, Conlon KC, Fernandez-Cruz L, Fingerhut A, Friess H, Hartwig W, Izbicki JR, Lillemoe KD, Milicevic MN, Neoptolemos JP, Shrikhande SV, Vollmer CM, Yeo CJ, Charnley RM; International Study Group on Pancreatic Surgery. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2014 Sep;156(3):591-600. doi: 10.1016/j.surg.2014.06.016. Epub 2014 Jul 22.
- Besselink MG, van Rijssen LB, Bassi C, Dervenis C, Montorsi M, Adham M, Asbun HJ, Bockhorn M, Strobel O, Buchler MW, Busch OR, Charnley RM, Conlon KC, Fernandez-Cruz L, Fingerhut A, Friess H, Izbicki JR, Lillemoe KD, Neoptolemos JP, Sarr MG, Shrikhande SV, Sitarz R, Vollmer CM, Yeo CJ, Hartwig W, Wolfgang CL, Gouma DJ; International Study Group on Pancreatic Surgery. Definition and classification of chyle leak after pancreatic operation: A consensus statement by the International Study Group on Pancreatic Surgery. Surgery. 2017 Feb;161(2):365-372. doi: 10.1016/j.surg.2016.06.058. Epub 2016 Sep 28.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del sistema endocrino
- Neoplasias por sitio
- Neoplasias
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Neoplasias de glándulas endocrinas
- Enfermedades pancreáticas
- Condiciones Patológicas, Signos y Síntomas
- Hallazgos morfológicos y microscópicos
- Neoplasias pancreáticas
- Márgenes de escisión
- Procedimientos quirúrgicos, operativo
- Procedimientos quirúrgicos del sistema digestivo
- Pancreaticoduodenectomía
Otros números de identificación del estudio
- 1702-09-2025
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .